Rift-lines within European regulatory framework for biosimilars when taking heterogeneity and variation during lifecycle of the reference biologic and the biosimilar into account /
Saved in:
Main Author: | |
---|---|
Format: | Electronic eBook |
Language: | English |
Published: |
Hamburg, Germany :
Anchor Academic Publishing,
2014.
|
Subjects: | |
Online Access: | An electronic book accessible through the World Wide Web; click to view |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000nam a2200000 i 4500 | ||
---|---|---|---|
001 | 0000182474 | ||
005 | 20171002064718.0 | ||
006 | m o d | ||
007 | cr cn||||||||| | ||
008 | 140416t20142014gw a ob 000 0 eng d | ||
020 | |z 9783954891870 | ||
020 | |z 9783954896875 (PDF) | ||
035 | |a (CaPaEBR)ebr10856569 | ||
035 | |a (OCoLC)878147377 | ||
040 | |a CaPaEBR |b eng |e rda |e pn |c CaPaEBR | ||
050 | 1 | 4 | |a RS189 |b .O863 2014eb |
082 | 0 | 4 | |a 572 |2 23 |
100 | 1 | |a Osmane, Malik, |e author. | |
245 | 1 | 0 | |a Rift-lines within European regulatory framework for biosimilars when taking heterogeneity and variation during lifecycle of the reference biologic and the biosimilar into account / |c Malik Osmane. |
264 | 1 | |a Hamburg, Germany : |b Anchor Academic Publishing, |c 2014. | |
264 | 4 | |c ©2014 | |
300 | |a 1 online resource (283 pages) : |b illustrations (some color) | ||
336 | |a text |2 rdacontent | ||
337 | |a computer |2 rdamedia | ||
338 | |a online resource |2 rdacarrier | ||
504 | |a Includes bibliographical references. | ||
588 | |a Description based on online resource; title from PDF cover (ebrary, viewed April 15, 2014). | ||
590 | |a Electronic reproduction. Palo Alto, Calif. : ebrary, 2014. Available via World Wide Web. Access may be limited to ebrary affiliated libraries. | ||
650 | 0 | |a Biological products. | |
650 | 0 | |a Drugs |x Generic substitution. | |
650 | 0 | |a Pharmaceutical biotechnology industry. | |
655 | 0 | |a Electronic books. | |
776 | 0 | 8 | |i Print version: |a Osmane, Malik. |t Rift-lines within European regulatory framework for biosimilars when taking heterogeneity and variation during lifecycle of the reference biologic and the biosimilar into account. |d Hamburg, Germany : Anchor Academic Publishing, c2014 |h 12 pages |z 9783954891870 |
797 | 2 | |a ebrary. | |
856 | 4 | 0 | |u http://site.ebrary.com/lib/daystar/Doc?id=10856569 |z An electronic book accessible through the World Wide Web; click to view |
908 | |a 170314 | ||
942 | 0 | 0 | |c EB |
999 | |c 171610 |d 171610 |